Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Dose Escalation and Expansion of JTX-2011 Alone or in Combination With Anti-PD-1 in Subjects With Advanced Solid Tumors (ICONIC)

Complete title: A Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects with Advanced Refractory Solid Tumor Malignancies

Research Study Number 20162312
 
Principal Investigator Scott Tykodi, MD
 
Phase I/II

Research Study Description

JTX-2011-101 is a Phase 1/2, open label, dose escalation and expansion clinical study of JTX-2011 alone or in combination with a fixed dose of nivolumab in subjects with advanced solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20162312
 
Contact Seattle Cancer Care Alliance Intake Office
 
Telephone 800-804-8824 / 206-606-1024
 

Keywords: Bladder Cancer; Breast Cancer; Esophageal Cancer; Gastrointestinal Cancer; Gynecological Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Melanoma; Mesothelioma; Pancreatic Cancer; Salivary Gland Cancer; Sarcoma; Solid Tumors; Thyroid Cancer; Neoplasms; Colorectal Neoplasms; Immunotherapy; Esophageal Diseases; Gastrointestinal Diseases

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials